Citations

Clear

4847 citation(s) found for "Yu, Eric".

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Bartlett, Nancy L. , Wilson, Wyndham H. , Pederson, Levi , Polley, Mei‐Yin C. , Pitcher, Brandelyn N., Cheson, Bruce D. , Friedberg, Jonathan W. , Staudt, Louis M. , Wagner‐Johnston, Nina D. , Blum, Kristie A. , Reddy, Nishitha , Chang, Julie , Chadburn, Amy , Mathew, Susan , Fisher, Richard I., Richards, Kristy L. , Leonard, John P. , Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D. , Maurer, Matthew J. , Kahl, Brad S. , Abramson, Jeremy S. , Winter, Jane N. , Gopal, Ajay K. , Schöder, Heiko , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | April 2, 2019 | Volume: 37 | Issue: 21 | Pages: 1790-1799

10.1200/jco.18.01994 | PMID 30939090 Get It

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma. PATIENTS AND METHODS Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety. RESULTS Between 2005 and 2013, 524 patients were registered; 491 eligible patients were included in the final analysis. Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5. At a median follow-up of 5 years, PFS was not statistically different between the arms (hazard ratio, 0.93; 95% CI, 0.68 to 1.27; P = .65), with a 2-year PFS rate of 78.9% (95% CI, 73.8% to 84.2%) for DA-EPOCH-R and 75.5% (95% CI, 70.2% to 81.1%) for R-CHOP. OS was not different (hazard ratio, 1.09; 95% CI, 0.75 to 1.59; P = .64), with a 2-year OS rate of 86.5% (95% CI, 82.3% to 91%) for DA-EPOCH-R and 85.7% (95% CI, 81.4% to 90.2%) for R-CHOP. Grade 3 and 4 adverse events were more common ( P < .001) in the DA-EPOCH-R arm than the R-CHOP arm, including infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.4% v 2.1%, respectively), and neuropathy (18.6% v 3.3%, respectively). Five treatment-related deaths (2.1%) occurred in each arm. CONCLUSION In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.
194 Diabetes and Erectile Dysfunction: A Special Population Analysis from a Penile Doppler Cohort of 1000 Patients
Shumate, Alice M., Schommer, Eric, Edwards, G., Cannizzo, Peter, Thomas, Charles L., Custer, Kenneth L., Shumate, A., Custer, K., Broderick, Gregory A.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S96-S96

10.1016/j.jsxm.2019.01.202 Get It

035. CANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH
Conklin, Laurie S. , Damsker, Jesse M. , Grayson, Peter C. , Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Sreih, Antoine G. , Ytterberg, Steven R. , Hoffman, Eric S., Monach, Paul A. , Parikh, Hemang M. , Cuthbertson, David , Khalidi, Nader , Moreland, Larry W. , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Merkel, Peter A.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez057.034 Get It

Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis
Bisch, Alexander L, Wheatley, Courtney M. , Baker, Sarah E. , Peitzman, Elizabeth R. , Iterson, Erik H. Van , Laguna, Theresa A. , Snyder, Eric M., Van Iterson, Erik H , Baker, Sarah E , Morgan, Wayne J.

Mayo Clinic

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine | March 29, 2019 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/1179548419835788 | PMID 30956528 Get It

Background: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems of the body and is characterized by mutation in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). Previous work has shown that a single dose of aβ-agonist increases cardiac output (Q) and stroke volume (SV) and decreases systemic vascular resistance (SVR) in healthy subjects. This effect is attenuated in patients with CF; however, the mechanism is unknown. Potential explanations for this decreased cardiovascular response to a β-agonist in CF include inherent cardiovascular deficits secondary to the CFTR mutation, receptor desensitization from prolonged β-agonist use as part of clinical care, or inhibited drug delivery to the bloodstream due to mucus buildup in the lungs. This study sought to determine the effects of endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular function in CF and to evaluate the relationship between cardiovascular function and CFTR F508del mutation. Methods: A total of 19 patients with CF and 31 healthy control subjects completed an assessment of Q (C 2 H 2 rebreathing), SV (calculated from Q and heart rate [HR]), Q and SV indexed to body surface area (BSA, QI, and SVI, respectively), SVR (through assessment of Q and mean arterial blood pressure [MAP]), and HR (from 12-lead electrocardiogram [ECG]) at rest along with plasma measures of EPI and NE. We compared subjects by variables of cardiovascular function relative to EPI and NE, and also based on genetic variants of the F508del mutation (homozygous deletion for F508del, heterozygous deletion for F508del, or no deletion of F508del). Results: Cystic fibrosis patients demonstrated significantly lower BSA (CF = 1.71 ± 0.05 m 2 vs healthy = 1.84 ± 0.04 m 2 , P = .03) and SVI (CF = 30.6 ± 2.5 mL/beat/m 2 vs healthy = 39.9 ± 2.5 mL/beat/m 2 , P = .02) when compared with healthy subjects. Cystic fibrosis patients also demonstrated lower Q (CF = 4.58 ± 0.36 L/min vs healthy = 5.71 ± 0.32 L/min, P = .03) and SV (CF = 54 ± 5.5 mL/beat vs healthy = 73.3 ± 4.5 mL/beat, P = .01), and a higher HR (CF = 93.2 ± 3.9 bpm vs healthy = 80.5 ± 2.7 bpm, P < .01) and SVR (CF = 2082 ± 156 dynes*s/cm −5 vs healthy = 1616 ± 74 dynes*s/cm −5 , P = .01) compared with healthy subjects. Furthermore, CF patients demonstrated a lower SV ( P < .01) corrected for NE when compared with healthy subjects. No significant differences were seen in HR or Q relative to NE, or SVR relative to EPI. Differences were seen in SV (F (2,14) = 7.982, P < .01) and SV index (F (2,14) = 2.913, P = .08) when patients with CF were stratified according to F508del mutation (number of deletions). Conclusions: Individuals with CF have lower cardiac and peripheral hemodynamic function parameters at rest. Furthermore, these results suggest that impairment in cardiovascular function is likely the result of F508del CFTR genotype, rather than receptor desensitization or inhibited drug delivery.
Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry
Bradley, Corey , Wang, Tracy Y., Li, Shuang , Robinson, Jennifer G. , Roger, Véronique L. , Goldberg, Anne C. , Louie, Michael J. , Lee, L. Veronica, Virani, Salim S. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Journal of the American Heart Association | March 27, 2019 | Volume: 8 | Issue: 7 | Pages: No page available

10.1161/jaha.118.011765 | PMID 30913959 Get It

Background Many adults eligible for statin therapy for cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons for statin underutilization, including noninitiation, refusal, and discontinuation. Methods and Results This study included the 5693 adults recommended for statin therapy in the PALM (Patient and Provider Assessment of Lipid Management) registry. Patient surveys evaluated statin experience, reasons for declining or discontinuing statins, and beliefs about statins and cardiovascular disease risk. Overall, 1511 of 5693 adults (26.5%) were not on treatment. Of those not on a statin, 894 (59.2%) reported never being offered a statin, 153 (10.1%) declined a statin, and 464 (30.7%) had discontinued therapy. Women (relative risk: 1.22), black adults (relative risk: 1.48), and those without insurance (relative risk: 1.38) were most likely to report never being offered a statin. Fear of side effects and perceived side effects were the most common reasons cited for declining or discontinuing a statin. Compared with statin users, those who declined or discontinued statins were less likely to believe statins are safe (70.4% of current users vs. 36.9% of those who declined and 37.4% of those who discontinued) or effective (86.3%, 67.4%, and 69.1%, respectively). Willingness to take a statin was high; 67.7% of those never offered and 59.7% of patients who discontinued a statin would consider initiating or retrying a statin. Conclusions More than half of patients eligible for statin therapy but not on treatment reported never being offered one by their doctor. Concern about side effects was the leading reason for statin refusal or discontinuation. Many patients were willing to reconsider statin therapy if offered.
BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin
Ruddy, Kathryn J. , Clark-Snow, Rebecca, Wickham, Rita , Binder, G. , Bailey, William L., Schmerold, Luke, Papademetriou, Eros , Navari, Rudolph M. , Roeland, Eric , LeBlanc, Thomas W. , Nipp, Ryan David , Potluri, Ravi C.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 26, 2019 | Volume: 17 | Issue: 3.5 | Pages: BPI19-019

10.6004/jnccn.2018.7192 Get It

Background: Avoiding acute care services can improve cancer care and reduce cost. The US Centers for Medicare and Medicaid Services’ (CMS) new oncology outcome measure (OP-35) defines 30-day post-chemotherapy inpatient (IP) and/or emergency department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic chemotherapy (HEC), and that NV-related IP use costs >$10,000; yet the incidence of avoidable acute care events involving NV is not well studied. Methods: We assessed chemotherapy courses using IBM Explorys electronic health records (4Q 2012–1Q 2018). We identified rates of IP/ED ≤30 days post-chemotherapy, and OP-35 toxicities (NV, anemia, dehydration, diarrhea, fever, neutropenia, pain, pneumonia, or sepsis) by ICD-9, ICD-10, procedure codes, and CMS criteria. We evaluated cisplatin, anthracycline + cyclophosphamide (AC), carboplatin (>14 days apart, as a proxy for AUC ≥4), oxaliplatin (OX), and other non-HEC chemotherapy. We assessed guideline adherence, defined as triple prophylaxis (NK1 RA + 5HT3 RA +dexamethasone) rates at HEC initiation. Results: In 17,609 HEC and 56,624 non-HEC courses, we observed 30-day IP/ED utilization in 29% and 19% of courses, respectively (Table 1). For HEC, 76% of IP/ED use involved ≥1 of the 10 CMS toxicities, most often anemia (42%), pain (41%), dehydration (24%), and NV (24%). Rates of all-cause IP/ED, IP/ED with OP-35 toxicity, and NV-related IP/ED were consistent for HEC and OX. Gaps in triple prophylaxis were common in HEC. Conclusion: Roughly one-third of patients receiving HEC or OX experienced IP/ED events ≤30 days after chemotherapy. Three-quarters of IP/ED events involved ≥1 of 10 OP-35 toxicities linked by CMS to potentially avoidable acute care; of these, one-third involved NV. NV-associated acute care use is considerable, costly, and potentially avoidable with better adherence to antiemesis guidelines.
Early Versus Late Computed Tomography and Nasal Endoscopy in the Diagnosis of Nasopharyngeal and Paranasal Sinus Malignancy
Marino, Michael J. , Hsieh, Mei‐Chin , Wu, Eric , Riley, Charles A. , Wu, Xiao‐Cheng , McCoul, Edward D.

Mayo Clinic

American Journal of Rhinology & Allergy | March 22, 2019 | Volume: 33 | Issue: 4 | Pages: 388-394

10.1177/1945892419838106 | PMID 30900468 Get It

Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) may be associated with an increased risk of subsequent diagnosis of nasopharyngeal carcinoma (NPC) or paranasal sinus cancer (PSC) in elderly Americans. The clinical utility of this association remains uncertain. Objective To compare early computed tomography (CT) or nasal endoscopy (NE) with late diagnostic studies for the diagnosis of NPC or PSC in elderly Americans with CRS or AR. Methods The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was queried from 2003 to 2011 and included 150 088 Medicare beneficiaries. Patients with a diagnosis of CRS or AR were examined for either NE or CT performed within 6 months of the exposure diagnosis. The risk of a cancer diagnosis was determined between the early and the late diagnostic groups. Results The relative risk of early cancer diagnosis with NE was 1.98 (95% confidence interval [CI], 1.60–2.43). The number needed to detect (NND) a case of cancer with NE was 503 (95% CI, 387–718). The relative risk of an early cancer diagnosis using CT was 3.40 (95% CI, 2.85–4.06) and NND was 221 (95% CI, 194–255). The stage of NPC or PSC for the late diagnostic group was not different from those with early NE ( P = .458) or CT ( P = .497). Overall survival was not different between diagnostic groups for NE ( P = .789) or CT ( P = .425). Conclusions Early NE or CT is associated with a higher likelihood of cancer diagnosis in elderly individuals with a diagnosis of CRS or AR. The clinical utility of this association is limited due to the low prevalence of these malignancies and lack of difference in disease stage and overall survival between diagnostic groups.
Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Tempero, Margaret A. , Malafa, Mokenge P. , Chiorean, E Gabriela, Czito, Brian G. , Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Wolpin, Brian M. , Al-Hawary, Mahmoud, Asbun, Horacio, Behrman, Stephen W. , Benson, Al B. , Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Ko, Andrew H. , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, Nakakura, Eric K. , O'Reilly, Eileen M, Obando, Jorge, Reddy, Sushanth, Thayer, Sarah P. , Wolff, Robert A. , Burns, Jennifer L, Zuccarino-Catania, Griselda, LoConte, Noelle K. , Chung, Vincent , Cardin, Dana B. , O’Reilly, Eileen M. , Fountzilas, Christos , Cha, Charles , Cardin, Dana B , LoConte, Noelle , O'Reilly, Eileen M , Chung, Vincent , Chiorean, E Gabriela, Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Al-Hawary, Mahmoud, Asbun, Horacio, Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Hawkins, William G , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, O'Reilly, Eileen M, Reddy, Sushanth, Burns, Jennifer L, Zuccarino-Catania, Griselda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 202-210

10.6004/jnccn.2019.0014 | PMID 30865919 Get It

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer
Fritz, Andrew J. , Gerrard, Diana L., Hong, David I. , Rose, Joshua T., Ghule, Prachi N. , Bolf, Eric L. , Gordon, Jonathan , Tracy, Kirsten M. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Heath, Jessica L. , Frietze, Seth , Zaidi, Sayyed K. , Carr, Frances E. , Lian, Jane B. , Stein, Janet L. , Fritz, A J , Stein, Gary S , van Wijnen, Andre J , Tracy, Kirsten M , Gillis, Noelle E. , Rodriguez, Princess D. , Hong, D., Gordon, J.A., Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Genes, Chromosomes and Cancer | March 15, 2019 | Volume: 58 | Issue: 7 | Pages: 484-499

10.1002/gcc.22731 | PMID 30873710 Get It

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial‐to‐mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer‐compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.